CTI BioPharma Stock Forecast, Price & News

+0.03 (+1.23 %)
(As of 04/16/2021 12:00 AM ET)
Today's Range
Now: $2.46
50-Day Range
MA: $2.94
52-Week Range
Now: $2.46
Volume851,665 shs
Average Volume939,430 shs
Market Capitalization$188.65 million
P/E RatioN/A
Dividend YieldN/A
CTI BioPharma Corp., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel targeted therapies for blood-related cancers in the United States. It develops pacritinib, an investigational oral kinase inhibitor with specificity for JAK2, FLT3, IRAK1, and CSF1R, which is in Phase III clinical trials for the treatment of adult patients with myelofibrosis. It has license and collaboration agreement with Teva Pharmaceutical Industries Ltd.; S*BIO Pte Ltd.; and Vernalis (R&D) Limited. The company was formerly known as Cell Therapeutics, Inc. and changed its name to CTI BioPharma Corp. in May 2014. CTI BioPharma Corp. was founded in 1991 and is headquartered in Seattle, Washington.
CTI BioPharma logo

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolNASDAQ:CTIC
Previous SymbolNASDAQ:CTICD
Year FoundedN/A



Sales & Book Value

Annual Sales$3.35 million
Book Value$0.31 per share


Net Income$-40,020,000.00


Market Cap$188.65 million
Next Earnings Date5/6/2021 (Estimated)


CTI BioPharma Corp. (NASDAQ:CTIC) Short Interest Update
April 1, 2021 |
CTI BioPharma: Q4 Earnings Snapshot
March 17, 2021 |
CTI BioPharma: Potential Light At End Of The Rainbow
February 27, 2021 |
Where Do Hedge Funds Stand On CTI Biopharma Corp. (CTIC)?
December 2, 2020 |
See More Headlines


Overall MarketRank

1.68 out of 5 stars

Medical Sector

294th out of 2,025 stocks

Pharmaceutical Preparations Industry

128th out of 772 stocks

Analyst Opinion: 3.5Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 2.5Valuation: 0.0 5 -4 -3 -2 -1 -
+0.03 (+1.23 %)
(As of 04/16/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive CTIC News and Ratings via Email

Sign-up to receive the latest news and ratings for CTIC and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

CTI BioPharma (NASDAQ:CTIC) Frequently Asked Questions

Is CTI BioPharma a buy right now?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for CTI BioPharma in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" CTI BioPharma stock.
View analyst ratings for CTI BioPharma
or view top-rated stocks.

What stocks does MarketBeat like better than CTI BioPharma?

Wall Street analysts have given CTI BioPharma a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but CTI BioPharma wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting CTI BioPharma?

CTI BioPharma saw a decrease in short interest during the month of March. As of March 15th, there was short interest totaling 401,300 shares, a decrease of 17.7% from the February 28th total of 487,800 shares. Based on an average daily volume of 625,000 shares, the short-interest ratio is presently 0.6 days. Currently, 0.6% of the shares of the stock are short sold.
View CTI BioPharma's Short Interest

When is CTI BioPharma's next earnings date?

CTI BioPharma is scheduled to release its next quarterly earnings announcement on Thursday, May 6th 2021.
View our earnings forecast for CTI BioPharma

How were CTI BioPharma's earnings last quarter?

CTI BioPharma Corp. (NASDAQ:CTIC) announced its earnings results on Tuesday, March, 16th. The biopharmaceutical company reported ($0.20) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.16) by $0.04.
View CTI BioPharma's earnings history

How has CTI BioPharma's stock been impacted by Coronavirus (COVID-19)?

CTI BioPharma's stock was trading at $0.8901 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, CTIC shares have increased by 176.4% and is now trading at $2.46.
View which stocks have been most impacted by COVID-19

When did CTI BioPharma's stock split? How did CTI BioPharma's stock split work?

CTI BioPharma shares reverse split on the morning of Tuesday, January 3rd 2017. The 1-10 reverse split was announced on Friday, December 9th 2016. The number of shares owned by shareholders was adjusted after the market closes on Friday, December 30th 2016. An investor that had 100 shares of CTI BioPharma stock prior to the reverse split would have 10 shares after the split.

What price target have analysts set for CTIC?

4 Wall Street analysts have issued 1 year price objectives for CTI BioPharma's shares. Their forecasts range from $3.00 to $13.00. On average, they anticipate CTI BioPharma's share price to reach $7.25 in the next year. This suggests a possible upside of 194.7% from the stock's current price.
View analysts' price targets for CTI BioPharma
or view top-rated stocks among Wall Street analysts.

Who are CTI BioPharma's key executives?

CTI BioPharma's management team includes the following people:
  • Dr. Adam R. Craig, Pres, CEO, Interim Chief Medical Officer & Director (Age 55, Pay $999.85k)
  • Mr. David H. Kirske, Exec. VP, CFO & Sec. (Age 67, Pay $526.09k)
  • Mr. Bruce J. Seeley, Exec. VP & COO (Age 57, Pay $614.84k)
  • Mr. Ed Bell, Sr. Director of Investor Relations
  • Mr. Jim Fong, Sr. VP of Global Operations
  • Mr. Bruce K. Bennett Jr., Sr. VP Global Pharmaceutical Operations (Age 69)
  • Mr. John Volpone, Sr. VP of Strategic Operations
  • Dr. Jennifer A. Smith, Sr. VP of Biometrics

What is James A. Bianco's approval rating as CTI BioPharma's CEO?

8 employees have rated CTI BioPharma CEO James A. Bianco on James A. Bianco has an approval rating of 27% among CTI BioPharma's employees. This puts James A. Bianco in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of CTI BioPharma's key competitors?

What other stocks do shareholders of CTI BioPharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other CTI BioPharma investors own include Edap Tms (EDAP), Energous (WATT), Adverum Biotechnologies (ADVM), Weatherford International (WFT), XOMA (XOMA), Sorrento Therapeutics (SRNE), SCYNEXIS (SCYX), Vaxart (VXRT), Dynavax Technologies (DVAX) and Trevena (TRVN).

What is CTI BioPharma's stock symbol?

CTI BioPharma trades on the NASDAQ under the ticker symbol "CTIC."

How do I buy shares of CTI BioPharma?

Shares of CTIC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is CTI BioPharma's stock price today?

One share of CTIC stock can currently be purchased for approximately $2.46.

How much money does CTI BioPharma make?

CTI BioPharma has a market capitalization of $188.65 million and generates $3.35 million in revenue each year. The biopharmaceutical company earns $-40,020,000.00 in net income (profit) each year or ($0.69) on an earnings per share basis.

How many employees does CTI BioPharma have?

CTI BioPharma employs 22 workers across the globe.

What is CTI BioPharma's official website?

The official website for CTI BioPharma is

Where are CTI BioPharma's headquarters?

CTI BioPharma is headquartered at 3101 WESTERN AVENUE SUITE 800, SEATTLE WA, 98121.

How can I contact CTI BioPharma?

CTI BioPharma's mailing address is 3101 WESTERN AVENUE SUITE 800, SEATTLE WA, 98121. The biopharmaceutical company can be reached via phone at 206-282-7100 or via email at [email protected]

This page was last updated on 4/18/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.